0000876661-24-000516.txt : 20240624
0000876661-24-000516.hdr.sgml : 20240624
20240624100121
ACCESSION NUMBER: 0000876661-24-000516
CONFORMED SUBMISSION TYPE: 25-NSE
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20240624
DATE AS OF CHANGE: 20240624
EFFECTIVENESS DATE: 20240624
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: TARO PHARMACEUTICAL INDUSTRIES LTD
CENTRAL INDEX KEY: 0000906338
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35463
FILM NUMBER: 241062367
BUSINESS ADDRESS:
STREET 1: 14 HAKTOR ST
CITY: HAIFA BAY
STATE: L3
ZIP: 26110
BUSINESS PHONE: 9143459001
MAIL ADDRESS:
STREET 1: THREE SKYLINE DR
CITY: HAWTHORNE
STATE: NY
ZIP: 10532
FORMER COMPANY:
FORMER CONFORMED NAME: TARO VIT INDUSTRIES LTD /ISRAEL/
DATE OF NAME CHANGE: 19930601
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: NEW YORK STOCK EXCHANGE LLC
CENTRAL INDEX KEY: 0000876661
ORGANIZATION NAME:
IRS NUMBER: 000000000
STATE OF INCORPORATION: NY
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: 11 WALL STREET
CITY: NEW YORK
STATE: NY
ZIP: 10005
BUSINESS PHONE: 212-656-2060
MAIL ADDRESS:
STREET 1: 11 WALL STREET
CITY: NEW YORK
STATE: NY
ZIP: 10005
FORMER COMPANY:
FORMER CONFORMED NAME: NEW YORK STOCK EXCHANGE INC
DATE OF NAME CHANGE: 19910628
25-NSE
1
primary_doc.xml
X0203
0000876661
NEW YORK STOCK EXCHANGE LLC
0000906338
TARO PHARMACEUTICAL INDUSTRIES LTD
001-35463
14 HAKITOR STHAIFA BAY
Haifa
26110
+972 9 971 1800
Ordinary Shares
17 CFR 240.12d2-2(a)(3)
Nicolas Connolly
Analyst, Regulation
2024-06-24
EX-99.25
2
ruleprovisionnotice.htm
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES
The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on July 05, 2024, pursuant to the provisions of Rule 12d2-2 (a).
[ X ] 17 CFR 240.12d2-2(a)(3) That on June 24, 2024 the instruments representing the securities comprising the entire class of this security came to evidence, by operation of law or otherwise, other securities in substitution therefore and represent no other right except, if such be the fact, the right to receive an immediate cash payment.
The merger between Taro Pharmaceutical Industries Ltd. and Libra Merger Ltd., a wholly owned subsidiary of Alkaloida Chemical Company ZRT, The Taro Development Corporation, and Sun Pharma Holdings, which are indirect subsidiaries of Sun Pharmaceutical Industries Ltd. became effective on June 24, 2024. Each Ordinary Share of Taro Pharmaceutical Industries Ltd. was exchanged for USD 43.00 in cash.
The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions this security was suspended from trading on June 24, 2024.